{"product_id":"mgnx-bcg-matrix","title":"(MGNX) MacroGenics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis MacroGenics, Inc. BCG Matrix helps you quickly see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and investment planning. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGC018, Phase 2 B7-H3 ADC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMGC018 is one of MacroGenics, Inc.’s top growth bets in solid tumors: a Phase 2 B7-H3 ADC aimed at a target linked to more than 10 tumor types, while global ADC sales are projected to top $20 billion by 2030. \u003c\/p\u003e\n\u003cp\u003eB7-H3 remains a high-interest oncology target, so a clean readout could drive faster partnering and better upfront and milestone terms. \u003c\/p\u003e\n\u003cp\u003eThat makes MGC018 a clear \"Star\" in the BCG Matrix, with high market potential and rising strategic value. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnoblituzumab, B7-H3 antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnoblituzumab targets B7-H3, a solid-tumor antigen linked to high unmet need and broad combo use across immuno-oncology. B7-H3 remains a growth area: the global oncology drug market was about $220 billion in 2025, and B7-H3 assets are still early in the cycle. If late-stage data stay positive, MacroGenics, Inc. could push this into a Star role and make it a lead franchise asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGD024, CD123 x CD3 DART\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMGD024, a CD123 x CD3 DART, fits a \"Star\" role because it targets hematologic malignancies where unmet need stays high, especially AML, which still drives about 20,000 new U.S. cases a year. CD123 T-cell engagers remain a fast-growing class, and clinical wins could lift MacroGenics' pipeline value fast. Strong data here could shift the asset from optionality to a core growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIMGC936, ADAM9 ADC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIMGC936, ADAM9 ADC is a newer solid-tumor asset, so it fits MacroGenics, Inc.'s high-upside but early-risk \"Star\" profile. ADCs remain one of oncology’s fastest-growing classes, with steady 2025-2026 deal flow and new readouts. If IMGC936 shows clear efficacy or safety separation, the solid-tumor market opportunity can be large.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNewer ADC, broad solid-tumor angle.\u003c\/li\u003e\n\u003cli\u003eHigh growth class, high readout risk.\u003c\/li\u003e\n\u003cli\u003eDifferentiation is the key value driver.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetifanlimab, partnered commercial asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetifanlimab is MacroGenics, Inc.’s strongest near-term monetization path outside MARGENZA because Incyte already commercializes Zynyz in approved immuno-oncology use. That gives MacroGenics exposure to an active market now, not just pipeline optionality. Any label expansion would lift growth, since the asset already has a cleared launch base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnered, approved, and revenue-linked\u003c\/li\u003e\n\u003cli\u003eBest near-term upside beyond MARGENZA\u003c\/li\u003e\n\u003cli\u003eLabel expansion would boost growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics’ Star Assets Could Drive Major Oncology Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc.’s Stars are the pipeline assets with the clearest high-growth pull: MGC018, Enoblituzumab, MGD024, and IMGC936. ADC sales are projected to top $20B by 2030, the global oncology drug market was about $220B in 2025, and AML still drives about 20,000 new U.S. cases a year, so each asset has real upside if data stay strong.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy it fits Star\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMGC018\u003c\/td\u003e\n\u003ctd\u003ePhase 2 B7-H3 ADC; broad solid-tumor demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMGD024\u003c\/td\u003e\n\u003ctd\u003eCD123 x CD3; AML growth tied to high need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMacroGenics’ BCG Matrix maps its pipeline by growth and share, showing where to invest, hold, or cut.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for MacroGenics to quickly spot stars, cash cows, and divestment risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGives a trusted source trail for MacroGenics, Inc. that strengthens credibility and speeds investor decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMARGENZA, only approved MacroGenics product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMARGENZA is MacroGenics’ only approved product, so it is the clearest cash cow in the portfolio. Approved in 2020, it gives the company real commercial presence and recurring product revenue, even if sales remain modest. In 2025, that approved status still matters most: it is the only marketed asset with direct revenue exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynyz royalties, retifanlimab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynyz royalties from retifanlimab give MacroGenics, Inc. a cleaner cash stream than pipeline R\u0026amp;D, because approved sales can turn into royalty income with no extra clinical spend. Zynyz was FDA-approved in 2023 for metastatic or recurrent locally advanced Merkel cell carcinoma, and each new sales dollar can feed MacroGenics, Inc. through its collaboration economics. It is one of the few lower-risk inflows tied to a marketed asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncyte collaboration funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIncyte collaboration funding is a cash cow for MacroGenics, Inc. because partner capital helps pay for development and cuts MacroGenics’ own cash burn. Incyte also shares program risk, so MacroGenics can keep advancing pipeline assets without funding the full bill alone. This is classic cash-supporting collaboration economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJanssen collaboration funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJanssen collaboration funding is a Cash Cow for MacroGenics, Inc. because partner receipts help pay R\u0026amp;D costs without needing broad product sales. For a small biotech, that steady collaboration cash is more reliable than speculative pipeline upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOffsets R\u0026amp;D burn\u003c\/li\u003e\n\u003cli\u003eSupports a lean biotech model\u003c\/li\u003e\n\u003cli\u003eSteady, non-commercial cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZai Lab and I-Mab partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZai Lab and I-Mab give MacroGenics, Inc. non-dilutive upside because the company keeps regional or strategic rights economics without funding the full buildout. These deals can trigger milestones and royalties, so they act like cash-generating assets even before product sales scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones add near-term cash.\u003c\/li\u003e\n\u003cli\u003eShared development cuts spend.\u003c\/li\u003e\n\u003cli\u003eRegional rights limit dilution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMARGENZA Powers MacroGenics; Partnerships Fuel the Rest\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMARGENZA is MacroGenics, Inc.’s only approved product, so it remains the main cash cow in 2025. Zynyz royalties add lower-risk inflow from an approved asset, while Incyte and Janssen collaboration receipts help fund R\u0026amp;D and cut cash burn. Zai Lab and I-Mab can also bring milestones and royalties without full buildout spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eCash role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMARGENZA\u003c\/td\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZynyz\u003c\/td\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncyte\u003c\/td\u003e\n\u003ctd\u003ePartner funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen\u003c\/td\u003e\n\u003ctd\u003ePartner funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMacroGenics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe MacroGenics, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content or watered-down version—just the full, ready-to-use file. It’s formatted for clear strategic review and immediate practical use. Download it once, and it’s yours to edit, print, or present.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGD014, HIV DART\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMGD014, HIV DART sits in MacroGenics, Inc.'s Dogs bucket because HIV is outside its core oncology focus. The program is a DART bispecific for HIV, but it does not drive the company’s main growth path. With MacroGenics, Inc. still centered on cancer assets, MGD014 looks like a niche R\u0026amp;D bet with limited commercial scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGD020, HIV DART\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMGD020, HIV DART is a non-core HIV asset for MacroGenics, and it fits Dogs in the BCG Matrix. The HIV antiretroviral market is mature, heavily genericized, and crowded, while MacroGenics' core spend and pipeline remain centered on oncology. That weak fit lowers strategic value and makes capital use harder to justify.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeplizumab, type 1 diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeplizumab sits outside MacroGenics, Inc.'s core cancer franchise, so it does not look like a strategic growth engine. The asset was FDA approved in 2022 for delaying type 1 diabetes, but it has not shown clear scale or material pull for MacroGenics. It ties up attention with limited fit, which is why it belongs in Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePRV-3279, autoimmune DART\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePRV-3279 sits in a crowded autoimmune DART field, where many rivals chase the same biology and clinical readouts, so execution risk stays high. MacroGenics, Inc. has clearer value drivers in oncology, while this program still has no approved label or near-term revenue path. That makes PRV-3279 a classic Dogs asset in the BCG view.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh crowding, high trial risk\u003c\/li\u003e\n\u003cli\u003eWeak near-term commercial visibility\u003c\/li\u003e\n\u003cli\u003eBetter capital use in oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy non-core programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy non-core programs at MacroGenics, Inc. are older assets that can still burn cash without building meaningful market share, so they sit well behind the company’s lead oncology programs. In 2025, MacroGenics kept capital focused on higher-value cancer assets, making these programs natural candidates for minimal spend or out-licensing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow strategic priority\u003c\/li\u003e\n\u003cli\u003eCash drag risk\u003c\/li\u003e\n\u003cli\u003eBetter fit for licensing\u003c\/li\u003e\n\u003cli\u003eFocus stays on oncology leads\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics’ Dogs: Non-Core Assets, Low Near-Term Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc.'s Dogs are mainly non-core HIV and autoimmune programs, plus legacy assets that do not fit its oncology-led strategy. They face weak commercial pull, high crowding, and no clear near-term revenue path, so capital use stays low-priority.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDogs signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMGD014\u003c\/td\u003e\n\u003ctd\u003eNon-core HIV, limited scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRV-3279\u003c\/td\u003e\n\u003ctd\u003eCrowded, no approved label\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLorigerlimab, PD-1 x CTLA-4\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLorigerlimab is a high-upside immuno-oncology question mark for MacroGenics, Inc. because PD-1 and CTLA-4 remain a huge checkpoint market, but rivals like Bristol Myers Squibb, Merck, and Roche make the bar very high. It needs clear efficacy and safety data to justify heavier spend, since dual-checkpoint combos can add toxicity and development risk. In BCG terms, it is worth watching, but only strong late-stage data can move it out of the question mark box.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTebotelimab, PD-1 x LAG-3\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTebotelimab sits in a growing LAG-3 checkpoint space, now validated by the 2022 FDA approval of relatlimab\/nivolumab. \u003c\/p\u003e\n\u003cp\u003eBut MacroGenics, Inc. still has unproven share here because tebotelimab is not yet a commercial product, so revenue impact remains zero for now. \u003c\/p\u003e\n\u003cp\u003eThat makes it a classic invest-or-pass question: high upside if data land well, but still a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGC018 expansion, new solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMGC018’s move into additional solid tumors could lift MacroGenics, Inc.’s addressable market well beyond one niche, since solid tumors make up most oncology cases worldwide. \u003c\/p\u003e\n\u003cp\u003eBut the asset still needs broader clinical proof across new cohorts, with safety and response durability key. \u003c\/p\u003e\n\u003cp\u003eIf later-stage data hold up, MGC018 could shift from a question mark toward star status in the BCG matrix. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnoblituzumab expansion, combination trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnoblituzumab is still a Question Mark in MacroGenics, Inc.'s BCG mix: it has higher-upside combinations in bladder, head and neck, and other solid tumors, but its market share is still unproven. MacroGenics reported no approved enoblituzumab revenue, so the program lives or dies on clinical data and partner interest. To avoid drifting toward Dog status, it needs clear response data and a sharper profile versus PD-1\/PD-L1-based regimens.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig upside if combinations work\u003c\/li\u003e\n\u003cli\u003eNo proven share or sales yet\u003c\/li\u003e\n\u003cli\u003eData, not hype, drives value\u003c\/li\u003e\n\u003cli\u003eDifferentiation is the key risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIMGC936 expansion, basket studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIMGC936 fits the Question Marks bucket: if basket studies show proof-of-concept, broader testing could open value across several solid tumors. The market is large, but current penetration is still low, so adoption depends on clear clinical signal. For MacroGenics, Inc., the key gate is not demand, it is whether the data can prove enough activity to justify expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad solid-tumor upside\u003c\/li\u003e\n\u003cli\u003eLow current market penetration\u003c\/li\u003e\n\u003cli\u003eProof-of-concept is the gate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics’ Question Marks: High Upside, No Revenue Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc.’s Question Marks are high-potential but unproven programs: lorigerlimab, tebotelimab, MGC018, enoblituzumab, and IMGC936. They sit in large oncology markets, but none has commercial sales, so value depends on late-stage data, safety, and partner interest. As of 2025, MacroGenics, Inc. still had no approved product revenue from these assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eBCG read\u003c\/th\u003e\n\u003cth\u003eKey gate\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLorigerlimab\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eDual-checkpoint data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTebotelimab\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eLAG-3 proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234699550985,"sku":"mgnx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mgnx-bcg-matrix.webp?v=1785724977","url":"https:\/\/dcfanalyst.com\/products\/mgnx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}